1. ALLA AKTIER
  2. NYHETER
  3. BIO-WORKS TECHNOLOGIES

Bio-Works Technologies

Nyheter Bio-Works Technologies Nyheter alla bolag

Bio-Works Technologies AB's Nomination Committee for the 2024 Annual General Meeting

MARKN.

Bio-Works Technologies AB's Nomination Committee shall consist of representatives of the three largest shareholders in the company in terms of voting rights who wish to be included in the Nomination Committee according to information from Euroclear Sweden AB as of the last banking day in September.

The Nomination Committee has now been constituted and consists of the following members:

  • Staffan Persson, Swedia Invest AB (Chairman of the Nomination Committee)
  • Erik Åfors, Calyptra AB
  • Dariush Hosseinian, Karkas Captial AB

In total, the Nomination Committee represents approximately 35 percent of the voting rights of all voting shares in the company. The Chairman of the Board is co-opted to the Nomination Committee as needed. The Annual General Meeting of Bio-Works Technologies AB will be held on Friday, May 24, 2024, at the company's head office in Uppsala, Sweden.

Shareholders who wish to submit proposals to Bio-Works Technologies AB's Nomination Committee can send an e-mail to info@bio-works.com subject "To the Nomination Committee" or a letter to Bio-Works Technologies AB, Virdings allé 18, 754 50 Uppsala, marked "To the Nomination Committee", no later than February 28, 2024.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0) 70 325 64 36.

About Bio-Works
Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works’ next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB, +46 (0) 8-528 00 399, info@fnca.se, is appointed Certified Adviser. For more information, www.bio-works.com.

Attachments
Bio-Works Technologies AB's Nomination Committee for the 2024 Annual General Meeting

Datum 2023-11-09, kl 09:36
Källa MFN
Bifogade filer
Bio-Works Technologies AB's Nomination Committee for the 2024 Annual General Meeting
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!